This weekend’s American Society of Clinical Oncology featured plenty of major data, and it also featured plenty of opportunities for us to catch up with executives around the industry. Below, we’re bringing you some of our favorite conversation snippets that
read morePharmas’ payments to doctors raise concerns about prescription bias and have often triggered bribery investigations, too. So, to win patients’ trust, transparency matters. Now one company plans to disclose all of its payments, even in regions where it’s not required.
read moreEven as the public and lawmakers zeroed in on major drug pricing scandals—Martin Shkreli, Valeant and EpiPen among them—routine price hikes on another drug largely went unnoticed. More: Women's hormone drug prices have climbed for years, but controversy hasn't ensued.
read moreFor years, the Centers for Medicare & Medicaid Services has been hearing concerns that laughing drug Nuedexta was being aggressively pushed by maker Avenair Pharmaceuticals and some doctors for questionable off-label use. Now the CMS is asking insurers to be
read moreWhy didn’t Mylan CEO Heather Bresch back down when attacked about EpiPen price hikes? To change the subject, she tells CNN. And how did she feel when her own father, a U.S. senator, attacked deals that move U.S. headquarters abroad
read moreAn international trial led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has shown that immunotherapy can benefit men with prostate cancer. More: Trial first to show immunotherapy benefit in prostate cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals